Ozempic and Other Semaglutide Medications vs. Bariatric Surgery for Weight Loss: A Comparison
Ozempic and other semaglutide medications have gained popularity for their effectiveness in aiding weight loss. However, a recent study conducted by researchers from New York University (NYU) reveals that bariatric surgery still outperforms these medications when it comes to shedding pounds.
The study compared sleeve gastrectomy and gastric bypass surgeries with semaglutide or tirzepatide, both of which are glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs mimic the natural GLP-1 hormone, which helps regulate appetite.
Using health records, the researchers matched individuals who had taken weight loss drugs with those who had undergone bariatric surgeries based on age, body mass index, and blood sugar levels. The results showed that individuals in the surgery group lost an average of 25.7 percent of their total body weight over two years, while those in the medication group only lost 5.3 percent.
One of the reasons for this significant difference is the adherence to treatment. Patients in the surgery group have more permanent results compared to those taking GLP-1 drugs, which require consistent usage. Even over shorter time frames, the study consistently showed that surgery yielded better weight loss results.
According to NYU surgical resident Avery Brown, the study highlights the discrepancy between clinical trial results and real-world outcomes of GLP-1 drugs. While clinical trials reported weight loss between 15 percent and 21 percent, the study found considerably lower weight loss rates in actual practice, with up to 70 percent of patients discontinuing treatment within a year.
Despite the superiority of bariatric surgery in terms of weight loss, GLP-1 drugs still offer beneficial results. With GLP-1 prescriptions on the rise, it is crucial to understand how these medications compare to surgical options and determine the best approach for individual patients.
It’s important to note that bariatric surgery not only aids in weight loss but also contributes to better blood sugar control. However, surgery is not without its drawbacks, as it is invasive, permanent, and requires strict adherence to post-operative diet and exercise regimens.
Future studies will aim to optimize GLP-1 outcomes, identify patients who may benefit more from bariatric surgery, and assess the role of out-of-pocket costs in treatment success. The research was presented at the ASMBS annual meeting in 2025.
Overall, while GLP-1 drugs offer a non-invasive option for weight loss, bariatric surgery remains the most effective method for significant and sustained weight reduction. Individual preferences, adherence to treatment, and healthcare provider guidance play crucial roles in determining the most suitable approach for achieving weight loss goals.
